Immunogenicity and protective efficacy of oligomeric human immunodeficiency virus type 1 gp140

被引:131
作者
Earl, PL
Sugiura, W
Montefiori, DC
Broder, CC
Lee, SA
Wild, C
Lifson, J
Moss, B
机构
[1] NIAID, Viral Dis Lab, NIH, Bethesda, MD 20892 USA
[2] Duke Univ, Med Ctr, Dept Surg, Durham, NC 27710 USA
[3] Panacos Pharmaceut, Gaithersburg, MD 20877 USA
[4] NCI, Frederick Canc Res & Dev Ctr, Retroviral Pathogenesis Lab, AIDS Vaccine Program,SAIC, Frederick, MD 21702 USA
关键词
D O I
10.1128/JVI.75.2.645-653.2001
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The biologically active form of the human immunodeficiency virus type 1 (HIV-1) envelope (Env) glycoprotein is oligomeric. We previously described a soluble HIV-1 IIIB Env protein, gp140, with a stable oligomeric structure composed of uncleaved gp120 linked to the ectodomain of gp41 (P. L. Earl, C. C. Broder, D. Long, S. A. Lee, J. Peterson, S. Chakrabarti, R W Doms, and B. Moss, J, Virol. 68:3015-3026, 1994). Here we compared the antibody responses of rabbits to gp120 and gp140 that had been produced and purified in an identical manner. The gp140 antisera exhibited enhanced cross-reactivity with heterologous Env proteins as well as greater neutralization of HIV-1 compared to the gp120 antisera. To examine both immunogenicity and protective efficacy, we immunized rhesus macaques with oligomeric gp140. Strong neutralizing antibodies against a homologous virus and modest neutralization of heterologous laboratory-adapted isolates were elicited. No neutralization of primary isolates was observed. However, a substantial fraction of the neutralizing activity could not be blocked by a V3 loop peptide. After intravenous challenge with simian-HIV virus SHN-HXB2, three of the four vaccinated macaques exhibited no evidence of virus replication.
引用
收藏
页码:645 / 653
页数:9
相关论文
共 79 条
[1]   Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection [J].
Baba, TW ;
Liska, V ;
Hofmann-Lehmann, R ;
Vlasak, J ;
Xu, WD ;
Ayehunie, S ;
Cavacini, LA ;
Posner, MR ;
Katinger, H ;
Stiegler, G ;
Bernacky, BJ ;
Rizvi, TA ;
Schmidt, R ;
Hill, LR ;
Keeling, ME ;
Lu, YC ;
Wright, JE ;
Chou, TC ;
Ruprecht, RM .
NATURE MEDICINE, 2000, 6 (02) :200-206
[2]   Antibody prevents the establishment of persistent arenavirus infection in synergy with endogenous T cells [J].
Baldridge, JR ;
McGraw, TS ;
Paoletti, A ;
Buchmeier, MJ .
JOURNAL OF VIROLOGY, 1997, 71 (01) :755-758
[3]   Vaccination with HIV 1 gp120 DNA induces immune responses that are boosted by a recombinant gp120 protein subunit [J].
Barnett, SW ;
Rajasekar, S ;
Legg, H ;
Doe, B ;
Fuller, DH ;
Haynes, JR ;
Walker, CM ;
Steimer, KS .
VACCINE, 1997, 15 (08) :869-873
[4]   Comparison of the antibody repertoire generated in healthy volunteers following immunization with a monomeric recombinant gp120 construct derived from a CCR5/CXCR4-using human immunodeficiency virus type 1 isolate with sera from naturally infected individuals [J].
Beddows, S ;
Lister, S ;
Cheingsong, R ;
Bruck, C ;
Weber, J .
JOURNAL OF VIROLOGY, 1999, 73 (02) :1740-1745
[5]   NEUTRALIZING ANTIBODIES TO HIV-1 IN SERONEGATIVE VOLUNTEERS IMMUNIZED WITH RECOMBINANT GP120 FROM THE MN STRAIN OF HIV-1 [J].
BELSHE, RB ;
GRAHAM, BS ;
KEEFER, MC ;
GORSE, GJ ;
WRIGHT, P ;
DOLIN, R ;
MATTHEWS, T ;
WEINHOLD, K ;
BOLOGNESI, DP ;
SPOSTO, R ;
STABLEIN, DM ;
TWADDELL, T ;
BERMAN, PW ;
GREGORY, T ;
IZU, AE ;
WALKER, MC ;
FAST, P .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1994, 272 (06) :475-480
[6]   Induction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in uninfected volunteers [J].
Belshe, RB ;
Gorse, GJ ;
Mulligan, MJ ;
Evans, TG ;
Keefer, MC ;
Excler, JL ;
Duliege, AM ;
Tartaglia, J ;
Cox, WI ;
McNamara, J ;
Hwang, KL ;
Bradney, A ;
Montefiori, D ;
Weinhold, KJ .
AIDS, 1998, 12 (18) :2407-2415
[7]   PROTECTION OF CHIMPANZEES FROM INFECTION BY HIV-1 AFTER VACCINATION WITH RECOMBINANT GLYCOPROTEIN GP120 BUT NOT GP160 [J].
BERMAN, PW ;
GREGORY, TJ ;
RIDDLE, L ;
NAKAMURA, GR ;
CHAMPE, MA ;
PORTER, JP ;
WURM, FM ;
HERSHBERG, RD ;
COBB, EK ;
EICHBERG, JW .
NATURE, 1990, 345 (6276) :622-625
[8]   A recombinant human immunodeficiency virus type 1 envelope glycoprotein complex stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits is an antigenic mimic of the trimeric virion-associated structure [J].
Binley, JM ;
Sanders, RW ;
Clas, B ;
Schuelke, N ;
Master, A ;
Guo, Y ;
Kajumo, F ;
Anselma, DJ ;
Maddon, PJ ;
Olson, WC ;
Moore, JP .
JOURNAL OF VIROLOGY, 2000, 74 (02) :627-643
[9]   FUSOGENIC SELECTIVITY OF THE ENVELOPE GLYCOPROTEIN IS A MAJOR DETERMINANT OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 TROPISM FOR CD4(+) T-CELL LINES VS PRIMARY MACROPHAGES [J].
BRODER, CC ;
BERGER, EA .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1995, 92 (19) :9004-9008
[10]   ANTIGENIC IMPLICATIONS OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 ENVELOPE QUATERNARY STRUCTURE - OLIGOMER-SPECIFIC AND OLIGOMER-SENSITIVE MONOCLONAL-ANTIBODIES [J].
BRODER, CC ;
EARL, PL ;
LONG, D ;
ABEDON, ST ;
MOSS, B ;
DOMS, RW .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (24) :11699-11703